Tumor necrosis factor-alpha augments tumor effects in isolated hepatic perfusion with melphalan in a rat sarcoma model.
Isolated hepatic perfusion (IHP) is an attractive approach to treating nonresectable liver tumors, because the effects of systemic chemotherapy are poor and its application is hampered by severe general toxicity. In clinical and experimental settings, the efficacy of isolated limb perfusion (ILP) with tumor necrosis factor-alpha (TNF alpha) in combination with melphalan to treat melanoma in transit and soft-tissue sarcoma has been well established. In an ILP model in rats, the authors previously observed synergistic anti-tumor effects of TNF and melphalan on BN 175 soft-tissue sarcoma extremity tumors. The aim of the current study was to determine whether similar synergy in anti-tumor effects could be achieved by treating experimental BN 175 soft-tissue sarcoma liver tumors by IHP using these agents. The authors found that IHP with TNF and melphalan resulted in a dramatic increase in regional concentrations of perfused agents with virtually no concomitant systemic leakage. Isolated hepatic perfusion with only carrier solution resulted in a significantly diminished growth rate of BN 175 liver tumors compared with the growth rate of tumors in nonperfused rats. Perfusion with melphalan alone resulted in minimal anti-tumor effects. Perfusion with only TNF had a slight growth-stimulatory effect on the BN 175 liver tumors, but no negative effects on tumor growth were observed. When TNF was added to melphalan, a dramatic anti-tumor effect was observed. Thus, as in the rat ILP setting, the anti-tumor effect is augmented when TNF is added to IHP with melphalan to treat BN 175 soft-tissue sarcoma tumor-bearing rats. Strikingly, the tumor response was potentiated at relatively low concentrations of TNF compared with concentrations that elicited synergy with melphalan in ILP.
Department of Surgical Oncology, University Hospital Rotterdam/Daniël den Hoed Cancer Center, Rotterdam, The Netherlands.
M G
MG
van Ijken
B
B
van Etten
J H
JH
de Wilt
S T
ST
van Tiel
T L
TL
ten Hagen
A M
AM
Eggermont
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000379:methods*; D003131:Combined Modality Therapy; D008099:Liver / Q000098:blood supply; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000628:therapy*; D008297:Male; D008558:Melphalan / Q000627:therapeutic use*; D051381:Rats; D012513:Sarcoma, Experimental / Q000188:drug therapy* / Q000628:therapy*; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage* / Q000032:analysis
D000276:Adjuvants, Immunologic; D018906:Antineoplastic Agents, Alkylating; D014409:Tumor Necrosis Factor-alpha; D008558:Melphalan